Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia (Q33961645)

30 July 2017

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia (English)

1 reference

30 July 2017

1 reference

2

1 reference

30 July 2017

3

J Curtis Nickel

1 reference

30 July 2017

1

Claus G Roehrborn

1 reference

30 July 2017

5

Gerald Andriole

1 reference

30 July 2017

Klaus Hoefner

4

1 reference

PubMed ID

12350480

30 July 2017

ARIA3001 ARIA3002 and ARIA3003 Study Investigators

series ordinal

6

1 reference

PubMed ID

12350480

30 July 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

30 July 2017

1 reference

30 July 2017

60

1 reference

30 July 2017

3

1 reference

30 July 2017

434-441

1 reference

The progression of benign prostatic hyperplasia: examining the evidence and determining the risk

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901905-2

7 January 2021

A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901905-2

7 January 2021

Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901905-2

7 January 2021

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901905-2

7 January 2021

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901905-2

7 January 2021

Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901905-2

7 January 2021

Steroid 5 alpha-reductase: two genes/two enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901905-2

7 January 2021

Expression and regulation of steroid 5 alpha-reductase 2 in prostate disease

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901905-2

7 January 2021

Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901905-2

7 January 2021

Discovery and development of GG745, a potent inhibitor of both isozymes of 5 alpha-reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901905-2

7 January 2021

Benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901905-2

7 January 2021

Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901905-2

7 January 2021

Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901905-2

7 January 2021

Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901905-2

7 January 2021

Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901905-2

7 January 2021

Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901905-2

7 January 2021

Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901905-2

7 January 2021

The so-called "placebo effect" in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901905-2

7 January 2021

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901905-2

7 January 2021

Medical therapy for benign prostatic hyperplasia: a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901905-2

7 January 2021

Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901905-2

7 January 2021

10.1016/S0090-4295(02)01905-2

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

12350480